Recursion acquires full interest in Rallybio's ENPP1 inhibitor program to develop a potential oral treatment for hypophosphatasia.

Recursion’s collaboration within Neuroscience and a GI Oncology indication for Roche and Genentech continues to bring unbiased novel biological insights to potential programs.

Rallybio (RLYB) announced that it received an equity milestone payment of $12.5M from Recursion Pharmaceuticals (RXRX). The milestone payment was ...

The REV102 program originated from a joint venture between Rallybio and Recursion focused on the discovery and development of novel, orally available small molecule inhibitors of ENPP1 for the ...

How to write a Java palindrome program for Strings Good programmers need to create code that efficiently solves problems, using various methods. A popular academic exercise is to create a program that ...

All told, Recursion is “deprioritizing” three clinical-stage programs, pausing another and winding down a single preclinical program in an undisclosed target, the company revealed in its first ...

Recursion Pharmaceuticals, Inc ((RXRX)) has held its Q2 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off ...

"Recursion's decade-long investment in AI is driving a decisive, data-led portfolio strategy," said Chris Gibson, Co-Founder and CEO of Recursion. "We are prioritizing high-potential programs to ...

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals – Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – ...